The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Characteristics and outcomes of young patients with MPNs
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, comments on the findings of a study investigating the characteristics and outcomes of a large cohort of young patients with myeloproliferative neoplasms (MPNs) diagnosed before 25 years of age. The study found that most young patients were females with essential thrombocythemia (ET). In addition, the study showed that while the molecular landscape of young patients was similar to that of older patients, young patients had a high incidence of complications and hematologic transformation, highlighting the need for better disease management in young patients with MPNs. This interview took place virtually.
Disclosures
Advisory boards for Novartis, Abbvie, BMS, AOP Orphan
